Johnson & Johnson has acquired medtech company Abiomed for $16.6 billion at $380 per share. Abiomed will now operate as a business unit within J&J's medtech segment.
The transaction will not have any impact on J&J's 2022 financial report. Following the acquisition, Abiomed's stock stopped trading, according to a Dec. 22 J&J news release.
"The completion of this acquisition allows Johnson & Johnson MedTech to expand our portfolio in the high growth cardiovascular markets, adding solutions for heart recovery to our global market leading Biosense Webster electrophysiology business," Ashley McEvoy, executive vice president and worldwide chair of medtech at J&J, said.